The US Centre for Disease Control Prevention’s Advisory Committee on Immunisation Practices (ACIP) has given its backing to GlaxoSmithKline’s newly approved shingles vaccine Shingrix over Merck & Co’s veteran vaccine Zostavax.
The US Centre for Disease Control Prevention’s Advisory Committee on Immunisation Practices (ACIP) has given its backing to GlaxoSmithKline’s newly approved shingles vaccine Shingrix over Merck & Co’s veteran vaccine Zostavax.
Horizon Pharma has enrolled the first patient in a Phase III clinical trial assessing its experimental medicine teprotumumab for moderate-to-severe active thyroid eye disease (TED).
Gilead has presented promising Phase II results for its experimental NASH drug GS-0976, showing significant reductions in the build up of liver fat and a marker of fibrosis.
The majority of patients at high risk of cardiovascular disease are not being started on statin therapy, suggests new research published in the British Journal of General Practice.
UK startup Echo, which recently launched an app enabling patients to order repeat NHS prescriptions from their smartphone, has raised £7 million in venture capital funding to help grow its offering.
Alexion’s rare disease therapy Soliris can now be used in the US to treat generalised myasthenia gravis in patients who are anti-acetylcholine receptor antibody-positive, offering this group the first new treatment option in more than 60 years.
A targeted combination therapy being developed by Novartis as adjuvant treatment for patients with a certain type of melanoma has been assigned breakthrough designation in the US.
Biogen and Eisai have expanded their existing collaboration agreement to develop and commercialise investigational therapies for Alzheimer’s Disease.
The Cancer Vanguard and Amgen have developed a simulation modelling tool to show health commissioners and trusts the financial benefits and challenges of delivering breast cancer medicines in a variety of community settings.
GP leaders have again voiced concerns over new rules introduced this week for charging for non-EU patients for non-emergency NHS treatment.
Muscular Dystrophy UK is campaigning for faster approval and funding for therapies for children and adults with muscle-wasting treatments, and warns that the wait for a government response to the Accelerated Access Review “adds to delays to new drugs”.
Public Health England has launched a major new campaign designed to further rein in inappropriate use of antibiotics, as estimates show that around 5,000 people in England alone die every year because of antimicrobial resistance.
With the awards ceremony edging closer, the Marketer of the Year and Communications Team of the Year finals concluded last week.
Organiser PharmaTimes Media is delighted to announce the launch of the 2018 edition of its annual competition for clinical researchers in the Americas.
PharmaTimes Media declares International Clinical Researcher of the Year 2018 ‘open for entry’.